Roche has announced that a late-stage study showed baloxavir marboxil, its new Tamiflu replacement, reduced symptoms in people at high risk of complications. The company found that the drug showed superior efficacy in speeding up improvement of symptoms versus a placebo.
The drug showed only modest benefits compared to Tamiflu in previously published studies.
The latest trial focused on adults at least 65 years old or patients with asthma, chronic lung disease, diabetes or heart disease.
U.S. regulators have accelerated their review and could make a decision by Dec. 24.
Read the Reuters report